Technology News and Research

RSS

UC San Diego Health System to receive HIMSS' Stage 7 Award

UC San Diego Health System has received the prestigious Stage 7 Award from HIMSS Analytics, a nationwide-system used to track electronic medical records (EMR) progress at hospitals and health systems.

7 Sep 2011

SYSU, ASU collaborate to develop early and predictive diagnostics for colorectal cancer

Arizona State University (ASU) and China's Sun Yat-Sen University (SYSU) have formalized a research collaboration aimed at developing early and predictive diagnostics to improve patient outcomes for colorectal cancer.

7 Sep 2011

Enrollment complete in DURECT's POSIDUR Phase III study for post-surgical pain

DURECT Corporation announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR known as BESST.

6 Sep 2011

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke.

6 Sep 2011

Concentric Medical launches Trevo Pro 4 device for acute ischemic stroke

Concentric Medical, Inc. today announced the full European launch of Trevo Pro 4 System. This next standard in Stentriever technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke.

6 Sep 2011

Comanche County Memorial Hospital chooses eClinicalWorks' EHR solution

eClinicalWorks, a market leader in ambulatory clinical systems, today announced that Oklahoma's Comanche County Memorial Hospital has chosen the eClinicalWorks comprehensive electronic health records (EHR) solution for its employed physicians across 28 locations that are multi-specialty.

6 Sep 2011

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has amended its agreement with Shiva Biomedical, LLC.

6 Sep 2011

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

Toshiba introduces Kalare Wireless X-ray system

Designed to improve productivity and efficiency in X-ray imaging, Toshiba America Medical Systems, Inc. has introduced the Kalare Wireless X-ray system. The Kalare Wireless includes the advanced technology from the original Kalare, plus a new wireless 14"x17" panel with a rotating bucky tray designed for optimal detector movement.

6 Sep 2011

Bariatric surgery is cost-effective but has long-term complications

The majority of people who undergo bariatric weight-loss surgery benefit from the procedure, but long-term complications and further surgery are not uncommon, according to a UK paper on late postoperative complications in the October issue of BJS, the British Journal of Surgery.

6 Sep 2011

Waters launches new single quadrupole mass detector at 2011 JAIMA Expo

Waters Corporation today introduced the Waters® SQ Detector 2, a new single quadrupole mass detector, at the 2011 JAIMA Expo.

6 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

McMaster team demonstrates essential role of AMPK enzyme in exercise

You may think your lack of resolve to get off the couch to exercise is because you're lazy, but McMaster University researchers have discovered it may be you are missing key genes.

6 Sep 2011

Sectra reports net sales of SEK 169.3 million for first quarter 2011

IT and medical technology company Sectra's profit after net financial items for the company's first quarter, May - July 2011, rose 25.6% to SEK 16.2 million (12.9), corresponding to a profit margin of 9.6% (7.5). The Group reports an operating profit of SEK 6.5 million (9.0) and net sales of SEK 169.3 million (172.8). Order bookings rose 13.8% to SEK 190.8 million.

6 Sep 2011

Researchers reveal mechanism behind how cells communicate

Cell communication is essential for the development of any organism. Scientists know that cells have the power to "talk" to one another, sending signals through their membranes in order to "discuss" what kind of cell they will ultimately become - whether a neuron or a hair, bone, or muscle. And because cells continuously multiply, it's easy to imagine a cacophony of communication.

6 Sep 2011

AMT, NIH enter exclusive license agreement for use of AAV5-based gene therapy vectors

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.

6 Sep 2011

Researchers discover novel way to increase amounts of antibiotics

A novel way of increasing the amounts of antibiotics produced by bacteria has been discovered that could markedly improve the yields of these important compounds in commercial production. It could also be valuable in helping to discover new compounds. With the ever-growing threat from antibiotic resistance, these tools will be very useful in ensuring that we have enough of these useful compounds in the future.

5 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Einstein researchers develop tuberculosis vaccine candidate

Researchers at Albert Einstein College of Medicine of Yeshiva University report in the September 4 online edition of Nature Medicine that they have developed a tuberculosis (TB) vaccine candidate that proved both potent and safe in animal studies.

5 Sep 2011